Drugs and rhabdomyolysis: From liver to kidney

Current Vascular Pharmacology

Volumn 13, Issue 6, 2015, Pages 725-737

  Barbano, Biagio ^a   Sardo, Liborio ^a   Gasperini, Maria L ^a   Gigante, Antonietta ^a   Liberatori, Marta ^a   di Lazzaro, Gianluca G ^a   di Mario, Francesca ^a   Dorelli, Barbara ^a   Amoroso, Antonio ^a   Cianci, Rosario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute kidney injury; Drugs metabolism; Liver disease; Rhabdomyolysis; Statins

Indexed keywords

ACETAZOLAMIDE; ALCOHOL; ANTIFUNGAL AGENT; ATORVASTATIN; BENZODIAZEPINE; CARBON MONOXIDE; COLCHICINE; CORTICOSTEROID; CREATINE KINASE; DAPTOMYCIN; DILTIAZEM; DIURETIC AGENT; FLUINDOSTATIN; FUROSEMIDE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVINOLIN; NEUROLEPTIC AGENT; PRAVASTATIN; PROPOFOL; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RANOLAZINE; ROSUVASTATIN; SALICYLIC ACID; SIMVASTATIN; TOXIN; UNINDEXED DRUG; WARFARIN;

ACIDURIA; ACUTE KIDNEY FAILURE; ALKALINIZATION; ARTICLE; CARDIOVASCULAR DISEASE; COMPARTMENT SYNDROME; CONNECTIVE TISSUE DISEASE; CRUSH SYNDROME; CYTOTOXICITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG METABOLISM; ELECTROLYTE DISTURBANCE; FASCIOTOMY; GENETIC DISORDER; HEART ARRHYTHMIA; HUMAN; HYDRATION; HYPERTHERMIA; HYPOTHYROIDISM; HYPOVOLEMIA; KIDNEY TUBULE DISORDER; LIVER DISEASE; MUSCLE CONTRACTION; MUSCLE DISEASE; MUSCLE ISCHEMIA; MUSCULAR VESSEL OCCLUSION; MYOSITIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RENAL REPLACEMENT THERAPY; RHABDOMYOLYSIS; SUBSTANCE ABUSE; TRAUMATIC RHABDOMYOLYSIS; VASOCONSTRICTION; VITAMIN D DEFICIENCY; ACUTE KIDNEY INJURY; ARRHYTHMIAS, CARDIAC; CHEMICALLY INDUCED; COMPARTMENT SYNDROMES; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; LIVER; METABOLISM; SKELETAL MUSCLE;

ACUTE KIDNEY INJURY; ARRHYTHMIAS, CARDIAC; COMPARTMENT SYNDROMES; CREATINE KINASE; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; LIVER; MUSCLE, SKELETAL; RHABDOMYOLYSIS;

EID: 84945960299     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161113666150130151839     Document Type: Article

References (110)

1. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361: 62-72.
2. Zimmerman JL, Shen MC. Rhabdomyolysis. Chest 2013; 144: 1058-65.
3. Bywaters EG, Beall D. Crush injuries with impairment of renal function. Br Med J 1941; 1: 427-32.
4. Bywaters EG, Delory GE, Rimington C, Smiles J. Myohaemoglobin in the urine of air raid casualties with crushing injury. Biochem J 1941; 35: 1164-8.
5. Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol 2000; 11: 1553-61.
6. Lang ST. Fondamenti di fisiologia cellulare in Fisiologia umana. 5th edition, Idelson-Gnocchi, Naples, Italy, 2008.
7. Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002; 25: 332-47.
8. Genthon A, Wilcox SR. Crush syndrome: a case report and review of the literature. J Emerg Med 2014; 46: 313-9.
9. Visweswaran P, Guntupalli J. Rhabdomyolysis. Crit Care Clin 1999; 15: 415-28.
10. Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med 2009; 67: 272-83.
11. Athyros VG, Katsiki N, Tziomalos K et al. GREACE Study Collaborative Group. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci 2013; 9: 418-26.
12. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-8.
13. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.
14. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90.
15. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649- 63
16. Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-- the PRIMO study. Cardiovasc Drugs Ther 2005; 19(6): 403- 14.
17. Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-64.
18. Better OS, Abbassi ZA. Early fluid resuscitation in patients with rhabdomyolysis. Nat Rev Nephrol 2011; 7: 416-22.
19. Westwood FR, Bigley A, Randall K, et al. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005; 33: 246-57.
20. Tiwari A, Bansal V, Chugh A, et al. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf 2006; 5: 651-66.
21. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49: 2231-7.
22. Caso G, Kelly P, McNurlan MA, et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99: 1409-12.
23. SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin induced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-99.
24. Ruano G, Windemuth A, Wu AH, et al. Mechanisms of statin induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011; 218: 451-6.
25. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010; 87: 130-3.
26. Feng Q, Wilke RA, Baye TM. Individualized risk for statininduced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 2012; 13: 579-94.
27. Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004; 4: 247-55.
28. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-15.
29. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004; 147: 956-65.
30. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.
31. Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 2011; 215(1): 23-9.
32. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency--a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf) 2009; 71(1): 154-5.
33. Hung YT, Yeung VT. Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis. Hong Kong Med J 2000; 6: 423-4.
34. Saha B, Maity C. Alteration of serum enzymes in primary hypothyroidism. Clin Chem Lab Med 2002; 40(6): 609-11.
35. Diekman T, Lansberg PJ, Kastelein JJ, et al. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 1995; 155(14): 1490-5.
36. Zhou S, Chan E, Li X, et al. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 2005; 1: 3-13.
37. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.
38. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-9.
39. Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538-44.
40. Plesnicar BK, Lasic JK, Plesnicar A. Quetiapine and elevated creatine phosphokinase (CK). Pharmacopsychiatry 2007; 40: 203- 4.
41. Gareri P, Segura-García C, De Fazio P, et al. Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities. Ann Pharmacother 2009; 43: 1354-9.
42. Bebarta VS, King JA, McDonough M. Proton pump inhibitorinduced rhabdomyolysis and hyponatremic delirium. Am J Emerg Med 2008; 26: 519.e1-2.
43. Dalakas M. Toxic and drug induced myopathies. J Neurol Neurosurg Psychiatry 2009; 80: 832-8.
44. Nawata Y, Kagami M, Nakajima H, et al. Chronic salicylate intoxication and rhabdomyolysis in a patient with scleroderma and Sjögren's syndrome. J Rheumatol 1994; 21: 357-9.
45. Terawaki H, Suzuki T, Yoshimura K, et al. A case of allopurinolinduced muscular damage in a chronic renal failure patient. Nihon Jinzo Gakkai Shi 2002; 44: 50-3.
46. Yu HJ, Song R, Kim HW, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol 2013; 53: 211-6.
47. Wang E, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of Pglycoprotein. Pharm Res 2001; 18: 800-6.
48. Hylton AC, Ezekiel TO. Rhabdomyolysis in a patient receiving ranolazine and simvastatin. Am J Health-Syst Pharm 2010; 67: 1829-31.
49. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003; 29: 1417-25.
50. Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofolrelated infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care 2009; 13: R169.
51. Motsch J, Roggenbach J. Propofol infusion syndrome. Anaesthetist 2004; 53: 1009-20.
52. Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med 2000; 28: 172-7.
53. Sauermann R, Rothenburger M, Graninger W, et al. Daptomycin: a review 4 years after first approval. Pharmacology 2008; 81:79-91.
54. Fernandez-Real JM, Ricart-Engel W. Hyponatremia and benzodiazepines result in rhabdomyolysis. Ann Pharmacother 1994; 28: 1200-1.
55. Marot A, Morelle J, Chouinard VA, et al. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg 2001; 66(2): 134-6.
56. Chiffoleau A, Trochu JN, Veyrac G, et al. Rhabdomyolysis in cardiac transplant recipient due to verapamil interaction with simvastatin and cyclosporin treatment. Therapie 2003; 58(2): 168-70.
57. Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 2002; 36(10): 1546-9.
58. Scarfia RV, Clementi A, Granata A. Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine. Ren Fail 2013; 35(7): 1056-7.
59. Dopazo C, Bilbao I, Lazaro JL, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patients. Transplant Proc 2009; 41: 1021-24.
60. Basic-Jukic N, Kes P, Bubic-Filipi L, et al. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient. Nephrol Dial Transplant 2010; 25(6): 2036.
61. Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988; 148: 1553-7.
62. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine 2005; 84: 377-85.
63. De Meijer AR, Fikkers BG, de Keijzer MH, et al. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med 2003; 29: 1121-5.
64. Woodrow G, Brownjohn AM, Turney JH. The clinical and biochemical features of acute renal failure due to rhabdomyolysis. Ren Fail 1995; 17: 467-74.
65. Knochel JP. Rhabdomyolysis and myoglobinuria. Annu Rev Med 1982; 33: 435-43.
66. Brown CV, Rhee P, Chan L, et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 2004; 56: 1191-6.
67. Paller MS. Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol 1988; 255: F539-44.
68. Baliga R, Zhang Z, Shah SV. Role of cytochrome P-450 in hydrogen peroxide-induced cytotoxicity to LLC-PK1 cells. Kidney Int 1996; 50: 1118-24.
69. Baliga R, Zhang Z, Baliga M, Shah SV. Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. Kidney Int 1996; 49: 362-9.
70. Patel RP, Diczfalusy U, Dzeletovic S, et al. Formation of oxysterols during oxidation of low density lipoprotein by peroxynitrite, myoglobin, and copper. J Lipid Res 1996; 37: 2361-71.
71. Grisham MB. Myoglobin-catalyzed hydrogen peroxide dependent arachidonic acid peroxidation. J Free Radic Biol Med 1985; 1: 227- 32.
72. Patel RP, Svistunenko DA, Darley-Usmar VM, et al. Redox cycling of human methaemoglobin by H2O2 yields persistent ferryl iron and protein based radicals. Free Radic Res 1996; 25: 117-23.
73. Ortiz de Montellano PR, Catalano CE. Epoxidation of styrene by hemoglobin and myoglobin. Transfer of oxidizing equivalents to the protein surface. J Biol Chem 1985; 260: 9265-71.
74. Moore KP, Holt SG, Patel RP, et al. A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J Biol Chem 1998; 273: 31731-7.
75. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2- like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87, 9383-7.
76. Dee G, Rice-Evans C, Obeyesekera S, et al. The modulation of ferryl myoglobin formation and its oxidative effects on low density lipoproteins by nitric oxide. FEBS Lett 1991; 294: 38-42.
77. Boutaud O, Roberts LJ 2nd. Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure. Free Radic Biol Med 2011; 51: 1062-7.
78. Zager RA. Studies of mechanisms and protective maneuvers in myoglobinuric acute renal injury. Lab Invest 1989; 60: 619- 29.
79. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199-210.
80. Holt S, Reeder B, Wilson M et al. Increased lipid peroxidation in patients with rhabdomyolysis. Lancet 1999; 353: 124.
81. Zager RA, Gamelin LM. Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. Am J Physiol 1989; 256: F446- 55.
82. Periáñez-Párraga L, Martínez-López I, Ventayol-Bosch P, et al. Drug dosage recommendations in patients with chronic liver disease. Rev Esp Enferm Dig 2012; 104: 165-84.
83. Gigante A, Di Lazzaro Giraldi G, Amoroso D, et al. Statins in chronic liver disease. Prevent Res 2013; 3: 247-52.
84. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine 1982; 61: 141-52.
85. Bonventre J, Shah S, Walker P, Humphreys M. Rhabdomyolysisinduced acute renal failure. In: The principles and practice of nephrology, 2nd Edition, Mosby, St. Louis, 1995; pp. 564-76.
86. Knochel JP. Rhabdomyolysis and myoglobinuria. Annu Rev Med 1982; 33: 435-43.
87. Corwin HL, Schreiber MJ, Fang LS. Low fractional excretion of sodium: occurrence with hemoglobinuric- and myoglobinuricinduced acute renal failure. Arch Intern Med 1984; 144: 981-2.
88. Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med 2007; 2: 210-8.
89. Nakahara K, Tanaka H, Masutani K, et al. The value of computed tomography and magnetic resonance imaging to diagnose rhabdomyolysis in acute renal failure. Nephrol Dial Transplant 1999; 14: 1564-7.
90. Abassi ZA, Hoffman A, Better OS. Acute renal failure complicating muscle crush injury. Semin Nephrol 1998; 18: 558-65.
91. Evans KJ, Greenberg A. Hyperkalemia: a review. J Intensive Care Med 2005; 20: 272-90.
92. Weisberg LS. Management of severe hyperkalemia. Crit Care Med 2008; 36: 3246-51.
93. Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990; 322: 825-9.
94. Heyne N, Guthoff M, Weisel KC. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361: 1412.
95. Visweswaran P, Guntupalli J. Rhabdomyolysis. Crit Care Clin 1999; 15:415-28.
96. Holt SG, Moore KP. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med 2001; 27: 803-11.
97. Zager RA, Foerder C, Bredl C. The influence of mannitol on myoglobinuric acute renal failure: functional, biochemical, and morphological assessments. J Am Soc Nephrol 1991; 2: 848-55.
98. Visweswaran P, Massin EK, Dubose TD Jr. Mannitol-induced acute renal failure. J Am Soc Nephrol 1997; 8: 1028-33.
99. Homsi E, Barreiro MF, Orlando JM, Higa EM. Prophylaxis of acute renal failure in patients with rhabdomyolysis. Ren Fail 1997; 19: 283-8.
100. Brown CV, Rhee P, Chan L, et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 2004; 56: 1191-6.
101. Brochard L, Abroug F, Brenner M, et al. An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010; 181: 1128-55.
102. Ho AM, Karmakar MK, Contardi LH, et al. Excessive use of normal saline in managing traumatized patients in shock: a preventable contributor to acidosis. J Trauma 2001; 51: 173-7.
103. Antoon JW, Chakraborti C. Corticosteroids in the treatment of alcohol-induced rhabdomyolysis. Mayo Clin Proc 2011; 86: 1005- 7.
104. Boutaud O, Moore KP, Reeder BJ, et al. Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis- induced renal failure. Proc Natl Acad Sci USA 2010; 107: 2699-704.
105. Aydogdu N, Atmaca G, Yalcin O, et al. Protective effects of Lcarnitine on myoglobinuric acute renal failure in rats. Clin Exp Pharmacol Physiol 2006; 33: 119-24.
106. Huer t a-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis an overview for clinicians. Crit Care 2005; 9: 158- 69.
107. Cruz DN, Bagshaw SM. Does continuous renal replacement therapy have a role in the treatment of rhabdomyolysis complicated by acute kidney injury? Semin Dial 2011; 24: 417-20.
108. Ronco C. Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care 2005; 9: 141-2.
109. Mikkelsen TS, Toft P. Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand 2005; 49: 859-64.
110. Tiwari A, Haq AI, Myint F, Hamilton G. Acute compartment syndromes. Br J Surg 2002; 89: 397.